- ►annals.org [PDF] RA DeFronzo - Annals of internal medicine, 1999 - Am Coll Physicians Type 2 diabetes mellitus is a chronic metabolic disorder that results from
defects in both insulin secretion and insulin action. An elevated rate of basal
hepatic glucose production in the presence of hyperinsulinemia is the pri- ... Cited by 782 - Related articles - BL Direct - All 14 versions
- ►adisonline.com [PDF] M Rendell - Drugs, 2004 - ingentaconnect.com The sulphonylureas act by triggering insulin release from the pancreatic β
cell. Abstract A specific site on the adenosine triphosphate (ATP)-sensitive
potassium channels is occupied by sulphonylureas leading to closure of the ... Cited by 86 - Related articles - BL Direct - All 7 versions
- ►annals.org S Stenman, A Melander, PH Groop, LC Groop - Annals of internal medicine, 1993 - Am Coll Physicians Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg
Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this? ...
What Is the Benefit of Increasing the Sulfonylurea Dose? Cited by 59 - Related articles - All 3 versions
- ►annals.org JA Colwell - Annals of internal medicine, 1996 - Am Coll Physicians Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg
Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this? ...
Objective: To review the results from the Veterans Affairs Cooperative ... Cited by 56 - Related articles - All 5 versions
LC Groop, RA Defronzo, L Luzi, A Melander - The Lancet, 1989 - Elsevier To examine whether hyperglycaemia impairs the absorption of sulphonylurea
agents, glipizide, which is rapidly and completely absorbed, was measured in
plasma from 12 healthy young subjects during various levels of ... Cited by 60 - Related articles - All 5 versions
Z Kerenyi, H Samer, R James, Y Yan, M … - Diabetes research and clinical practice, 2004 - Elsevier Aim: To compare the efficacy of combination therapy using rosiglitazone (8 mg
per day) and glibenclamide (7.5 mg per day) with upward titration of
glibenclamide as monotherapy (maximum dose=15 mg per day) in reducing HbA ... Cited by 50 - Related articles - All 8 versions
- ►cardiovascres.org CE Schotborgh, AAM Wilde - Cardiovascular research, 1997 - cardiovascres.org Sulfonylurea derivatives are hypoglycemic drugs frequently used in the treatment
of non-insulin-dependent diabetes mellitus (NIDDM). In the β-cell sulfonylureas
act by blocking ATP-sensitive potassium channels (K.ATP channels). In ... Cited by 42 - Related articles - All 6 versions
- ►adisonline.com [PDF] ADB Harrower - Drug safety, 2000 - ingentaconnect.com Abstract The sulphonylurea drugs have been the mainstay of oral treatment for
patients with diabetes mellitus since they were introduced. In general, they are
well tol- erated, with a low incidence of adverse effects, although there ... Cited by 44 - Related articles - BL Direct - All 8 versions
J Bryan, A Crane, WH Vila-Carriles, AP … - Current pharmaceutical design, 2005 - ingentaconnect.com Abstract: ATP-sensitive K + channels, termed K ATP channels, provide a link
between cellular metabolism and membrane electrical activity in a variety of
tissues. Channel isoforms have been identified and are targets for ... Cited by 37 - Related articles - BL Direct - All 4 versions
DSH Bell - Clinical therapeutics, 2004 - Elsevier A comprehensive search of the MEDLINE and PubMed databases for the years 1966 to
present anda thorough review of abstracts of recently presented clinical trials
were used to identify relevant literature on dosing conversion and ... Cited by 25 - Related articles - All 4 versions
